Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6720 |
Vatalanib dihydrochloride
CGP-797870 dihydrochloride,ZK-222584 dihydrochloride,Vatalanib 2HCl,PTK787 dihydrochloride,Vatalanib (PTK787) 2HCl,CGP-79787 dihydrochloride,瓦他拉尼 |
Apoptosis; VEGFR; PDGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Vatalanib dihydrochloride (PTK787 dihydrochloride) 是一种VEGFR2/KDR 的抑制剂,其IC50值为37nM。 | |||
T17219 |
Vatalanib free base
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Vatalanib free base 是一种 VEGFR2/KDR 的抑制剂,其IC50=37nM。 | |||
T71897 |
Vatalanib succinate
|
||
Vatalanib succinate is a VEGFR, PDGFR-β, c-Kit, c-Fms, and aromatase inhibitor. | |||
T69888 |
SB02024
|
||
SB02024 is a VPS34 inhibitor. SB02024 activates cGAS-STING signaling and sensitizes tumors to STING agonist. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity... | |||
T69487 | ZK-261557 | ||
ZK-261557 is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors. |